Central precocious puberty (CPP) is characterised by the premature activation of the hypothalamic-pituitary-gonadal (HPG) axis, resulting in early development of secondary sexual characteristics. This ...

Ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHas) is a standard of care for premenopausal patients with high-risk stage II/III hormone receptor–positive breast ...

A publicly listed, clinical-stage biopharmaceutical company operating across North America, Europe, and the Middle East. The company runs mid-stage clinical development programs in multiple ...

PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said detailed clinical data from early-stage studies of its long-acting ...